About the Editors
Dr Ayalew Tefferi
Dr Ayalew Tefferi was born in Addis Ababa, Ethiopia, and migrated to the United States in 1982 after completing his medical school education at the University of Athens in Athens, Greece. Dr Tefferi received his Hematology training at the Mayo Clinic in Rochester MN before joining the staff at the Mayo Clinic College of Medicine, Division of Hematology in the Department of Medicine. He has been a full professor in Hematology and Internal Medicine since 2001.
Dr Tefferi is primarily engaged in direct patient care and sees patients every afternoon. His clinical and laboratory interests focus on myeloid disorders including polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia, myelodysplastic syndromes, acute leukemia, eosinophilic disorders and systemic mastocytosis. He also serves as division resource for anemia, porphyria, hemochromatosis and hemoglobinopathies.
Dr Tefferi's academic and research achievements include over 1000 publications including books, book chapters, original articles, reviews, editorials, letters, and abstracts. Dr Tefferi serves as associate or section editor for the Mayo Clinic Proceedings, Leukemia, American Journal of Hematology, European Journal of Hematology, and Hematological Oncology. He is also in the editorial board of several other journals including Journal of Clinical Oncology, Blood, Cancer, Leukemia Research, Acta Haematologica, and Leukemia and Lymphoma. Dr Tefferi has given more than 700 national and international invited lectureships and serves as faculty for the annual Hematology and Oncology Board review courses at George Washington University in Washington DC, Cancer Medicine and Hematology offered by Harvard institutes in Boston MA, and MD Anderson Cancer Center in Houston TX.
S. Vincent Rajkumar, MD
Dr Rajkumar is Professor of Medicine at the Mayo Clinic, Rochester, Minnesota, and Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He is also the Chair of the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. Dr Rajkumar has a multi-faceted research program involving clinical trials, epidemiologic studies, and laboratory research. He has led several clinical trials investigating the role of new agents in myeloma, including the pivotal trials that led to the approval of thalidomide in myeloma in the United States. As chair of the ECOG myeloma committee he leads the design and implementation of several national phase III randomized trials for the disease. Dr Rajkumar also leads several large epidemiologic studies investigating the prevalence and progression of various monoclonal gammopathies. The research is primarily funded by the National Institutes of Health, USA. His current laboratory research is focused on investigating novel agents in myeloma, and studying the role of angiogenesis in various plasma cell disorders. He has published more than 230 peer-reviewed papers primarily in the field of myeloma and related plasma cell disorders. In addition to his editorial role in the Blood Cancer Journal, Dr Rajkumar currently serves as the Section Editor for multiple myeloma and related disorders for Leukemia and as an Associate Editor for the Mayo Clinic Proceedings.
Omar Abdel-Wahab, Memorial-Sloan Kettering Cancer Center, USA
Stephen Ansell, Mayo Clinic, USA
Naseema Gangat, Mayo Clinic, USA
Andreas Hochhaus, University Medical Center Jena, Germany
Sagar Lonial, Winship Cancer Institute, Emory University, USA
Mohamad Mohty, CHU de Nantes, France
Raajit Rampal, Memorial-Sloan Kettering Cancer Center, USA
Eric Solary, Institut de Cancérologie Gustave, Roussy, France
Alessandro Vannucchi, University of Florence, Italy